Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores

BACKGROUND: Licensed systemic treatment options for platinum-sensitive recurrent ovarian cancer are platinum-based chemotherapy and maintenance treatment with bevacizumab and poly (ADP-ribose) polymerase inhibitors. For platinum-resistant disease, several non-platinum options are available. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Broekman, K.E., van Kruchten, M., van Tinteren, H., Sessa, C., Jalving, M., Reyners, A.K.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358417/
https://www.ncbi.nlm.nih.gov/pubmed/34371383
http://dx.doi.org/10.1016/j.esmoop.2021.100229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358417/
https://www.ncbi.nlm.nih.gov/pubmed/34371383
http://dx.doi.org/10.1016/j.esmoop.2021.100229

Ejemplares similares